Michael Palfreyman

Michael G. Palfreyman, BPharm, Ph.D., DSc., MRPharmS Tel: 617-314-6439; Cell: 978-884-4861; International Cell: 372-5957-5122; Fax: 781-893-1329 E-mail: [email protected]; Skype: michael.palfreyman1 Michael G. Palfreyman is a seasoned leader in the biotechnology and pharmaceutical industries with over 35 years' experience in leadership positions. Dr. Palfreyman is President, Palfreyman BioPharm Advisors, Inc.; Chairman of the Board, Amakem, NV (www.amakem.com) and Director, Oculogics, Inc (www.oculogics.com). In addition, he is Head, R&D; Diligence at Torrey Pines Investment (www.torreypinesinv.com) and Senior R&D; Diligence at ChemRar (www.chemrar.ru); Head, Translational R&D; at ChemDiv, Inc.(www.chemdiv.com) as well as Senior Scientific Advisor for EnVivo Pharmaceuticals, Inc. (www.envivopharma.com), and Scientific Advisor to Avineuro,Inc. (www.avineuro.com), Aminex Therapeutics, (www.aminextherapeutics.com), and NeuroNascent, Inc. (www.neuronascent.com). Previously, Michael was VP, Program Management & Product Development at EnVivo Pharmaceuticals where he was responsible for the late stage discovery and preclinical development of two CNS drugs now demonstrating efficacy in clinical testing. As a co-founder NOVACE Corporation, Michael worked closely with Investors and Biotechnology Companies to bring products from discovery through to the value point of clinical validation. Before joining NOVACE, Michael held a number of executive positions at Psychiatric Genomics, Scriptgen (Anadys) Pharmaceuticals as well as Marion Merrell Dow Research Institute (Sanofi-Aventis). In addition to overseeing research programs in Psychiatric, Neurological, Cardiovascular, Cancer, Infectious, Metabolic and Respiratory Disorders, Dr. Palfreyman's own research included discovery and development of a number of psychotherapeutic compounds for treatment of psychosis, depression, stroke, epilepsy, emesis, Parkinsons, and Alzheimers diseases. Many of these compounds have entered clinical development and a number have reached the marketplace. He has been an invited speaker and chairperson for a number of international and national conferences, is co-inventor on 35 issued US patents, 3 pending patents and co-author of over 150 scientific articles and book chapters.